BSX - Boston Scientific Corporation
36.56 0.00 (0.00%)
After hours: 5:19PM EST
| Previous Close | 36.15 |
| Open | 36.59 |
| Bid | 34.17 x 1100 |
| Ask | 0.00 x 4000 |
| Day's Range | 36.16 - 36.95 |
| 52 Week Range | 24.79 - 39.44 |
| Volume | 5,806,524 |
| Avg. Volume | 7,639,151 |
| Market Cap | 50.592B |
| Beta (3Y Monthly) | 0.96 |
| PE Ratio (TTM) | 75.69 |
| EPS (TTM) | 0.48 |
| Earnings Date | Jan 30, 2019 - Feb 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.41 |
- PR Newswire•4 hours ago
Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Delaware Court Rules Edwards Lifesciences Infringes Boston Scientific Patent MARLBOROUGH, Mass. , Dec. 11, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that a jury in ...
- TheStreet.com•10 hours ago
Shire, Abbott Labs May Pace Healthcare Stocks in 2019
Shire is a pharmaceutical company, with a wide range of products approved for use around the world. Some of the more familiar drugs the company produces include Adderall, prescribed for adult ADD, and Pentasa, used to treat Crohn's and other inflammatory bowel diseases. The company possesses both strength and weakness, and both are evident in the most recent quarterly report.
Market Realist•13 hours agoWill GE’s Healthcare Unit Spin-Off Increase Shareholder Wealth?
Why Has General Electric Stock Struggled in 2018? The Healthcare segment is the fourth-largest contributor to General Electric’s total revenues. As part of the company’s major restructuring plan in June, General Electric intends to spin off the segment and turn it into a standalone entity.
- American City Business Journals•15 hours ago
Startup spun out of NxThera ahead of Boston Scientific deal raises $18M
Maple Grove-based Francis Medical will put the funding toward clinical trials as it prepares to roughly double its 10-person staff over the next year.
- Insider Monkey•3 days ago
Boston Scientific Corporation (BSX) Hedge Funds Are Snapping Up
At Insider Monkey we follow around 700 of the best-performing investors and even though many of them lost money in the last couple of months (70% of hedge funds lost money in October whereas S&P 500 ETF lost about 7%), the history teaches us that over the long-run they still manage to beat the market, […]
- GlobeNewswire•5 days ago
Research Report Identifies CoreLogic, Altisource Portfolio Solutions S.A, Old Dominion Freight Line, Emerson Electric, Boston Scientific, and Natural Grocers by Vitamin Cottage with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Market Realist•5 days agoHow Boston Scientific Stock Has Performed in the Past Month
After a stellar ride from $25.32 on January 4, 2018, to $39.04 on October 2, Boston Scientific stock (BSX) has fluctuated in the past month. From $35.38 on October 29, 2018, Boston Scientific stock rose to $38.60 on November 9, 2018. Boston Scientific’s revenue grew by 7.7% from $2.22 billion in the third quarter of 2017 to $2.39 billion in the third quarter of 2018.
- ACCESSWIRE•6 days ago
Today's Research Reports on Trending Tickers: Boston Scientific and Abbott Laboratories
Boston Scientific’s stock moved 5.17% lower Tuesday, to close the day at $36.52. The stock recorded a trading volume of 8,966,181 shares, which was above its three months average volume of 7,581,259 shares. In the last year, Boston Scientific’s shares have traded in a range of 24.54 - 39.44.
- PR Newswire•9 days ago
Boston Scientific to Participate in 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference
MARLBOROUGH, Mass. , Dec. 3, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in the 2018 BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, ...
- GOBankingRates•9 days ago
14 of the Best Performing Stocks in 2018
See which stocks made major moves in 2018.
- Zacks•11 days ago
Boston Scientific (BSX) Outpaces Stock Market Gains: What You Should Know
Boston Scientific (BSX) closed at $37.67 in the latest trading session, marking a +1.7% move from the prior day.
- Zacks•13 days ago
HRC or BSX: Which Is the Better Value Stock Right Now?
HRC vs. BSX: Which Stock Is the Better Value Option?
Market Realist•13 days agoAnalysts Remain Bullish on Align Stock
In November 2018, of the total 15 analysts covering Align Technology (ALGN), 13 analysts have given Align stock a “buy” or higher rating, and two analysts have given it a “hold” rating. The mean rating for Align Technology stock is 1.67 with a target price of $317.36, implying an upside potential of 43.8% over Align Technology’s closing price of $220.71 on November 27, 2018.
Market Realist•13 days agoHow Is Align Technology Positioned in November?
Align Technology (ALGN) is focused on establishing its Invisalign clear aligners as the standard method for treating malocclusion and establishing its iTero intraoral scanner as the scanning device of choice for 3D digital scans.
Market Realist•13 days agoWhat Investors Should Know about Align’s Operational Performance
For fiscal 2018 and 2019, Align Technology’s gross margins are expected at 73.97% and 73.69%, respectively, as compared with gross margins of 75.81% for fiscal 2017. In comparison, the fiscal 2018 gross margins of peers Abbott Laboratories (ABT), Boston Scientific (BSX), and Edwards Lifesciences (EW) are expected at 59.29%, 72.08%, and 74.83%, respectively.
Market Realist•13 days agoEdwards Lifesciences Stock: Analysts Remain Bullish
In November, among the 22 analysts covering Edwards Lifesciences (EW), 13 recommended a “buy” or higher rating, seven recommended a “hold” rating, and two recommended a “sell” or lower rating. The mean rating for Edwards Lifesciences stock is 2.32 with a target price of $161.53, which implies an upside potential of 4.5% over Edwards Lifesciences’ closing price of $154.52 on November 27.
Market Realist•13 days agoWhy Analysts Are Mostly Positive on Boston Scientific Stock
Boston Scientific (BSX) stock rose from $24.79 at the close of market on December 29, 2017, to $34.80 at the close of market on November 23, 2018, reflecting a rise of ~40% year-to-date. On November 23, Boston Scientific stock closed at $34.80, a ~42% rise from its 52-week low of $24.54 on December 6, 2017.
Market Realist•13 days agoTaking Stock of Edwards Lifesciences’ Performance
A strong operational performance and steady uptick in Edwards Lifesciences’ (EW) stock price has kept investors interested in the stock in 2018. In this series, we’ll discuss Edwards Lifesciences’ financials, segmental performance, analysts’ views on the stock, and the company’s valuation metrics. Edwards Lifesciences is a leader in patient-focused solutions for structural heart disease and critical care monitoring.
Market Realist•13 days agoEdwards Lifesciences’ Operational Performance
Edwards Lifesciences’ (EW) cost of sales increased from $213.3 million in the third quarter of 2017 to $224.9 million in the third quarter. The company’s gross profit grew from $608.2 million in the third quarter of 2017 to $681.7 million in the third quarter due to the improved product mix.
- CNBC•14 days ago
Cramer's lightning round: Citigroup and JP Morgan are my only bank stock picks
Jim Cramer fires off his answers to callers' stock questions, including a query on a regional banking play.
- PR Newswire•15 days ago
Boston Scientific to Participate in Citi's 2018 Global Healthcare Conference
MARLBOROUGH, Mass. , Nov. 27, 2018 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in Citi's 2018 Global Healthcare Conference on Thursday, December 6, 2018 in New York City ...
Associated Press•15 days agoSpinal-cord stimulators help some patients, injure others
Desperate for relief after years of agony, Jim Taft listened intently as his pain management doctor described a medical device that could change his life. Taft's stimulator failed soon after it was surgically implanted. For years, medical device companies and doctors have touted spinal-cord stimulators as a panacea for millions of patients suffering from a wide range of pain disorders, making them one of the fastest-growing products in the $400 billion medical device industry.
- CNBC•15 days ago
Google asks for refund of campaign contribution to embattled Sen. Cindy Hyde-Smith
Google has asked Sen. Cindy Hyde-Smith for a refund of its $5,000 campaign contribution because of controversial comments by the Mississippi Republican, who faces a runoff election against Democrat Mike Espy on Tuesday, the company confirmed to CNBC on Monday. Ernst & Young, Amgen, AT&T, Boston Scientific, Leidos, Pfizer, Union Pacific and the Office of the Commissioner of Major League Baseball have all asked Hyde-Smith to refund their contributions, in light of her comments about attending a public hanging and suppressing voter turnout.
Market Realist•16 days agoWhat Analysts Recommend for Hologic Stock
In November 2018, of the total 20 analysts covering Hologic (HOLX), ten analysts have given the stock a “buy” or higher rating, and ten analysts have given it a “hold” rating. The mean rating for Hologic stock is 2.3 with a target price of $45.09, implying an upside potential of 8.5% over Hologic’s closing price of $41.54 on November 21, 2018.
Market Realist•16 days agoA Look at Hologic’s Gross Margin Trend
Hologic’s (HOLX) cost of product revenues increased from $881.8 million in fiscal 2017 to $886.6 million in fiscal 2018. Its amortization on intangible assets increased from $297.1 million in fiscal 2017 to $319.4 million in fiscal 2018 due to an increase associated with the Cynosure acquisition partially offset by lower amortization expenses related to the sale of its blood screening business. The company’s gross margin contracted from 64.07% in fiscal 2017 to 62.72% in fiscal 2018.
